Saundra Pelletier

At-a-Glance

CEO of Evofem Biosciences, Inc. since 2013, a commercial-stage biopharmaceutical company focused on women's sexual and reproductive health.
Led the launch of Phexxi in September 2020, the first and only FDA-approved hormone-free, on-demand birth control.
Oversaw the acquisition of SOLOSEC in July 2024, an FDA-approved single-dose oral antimicrobial for trichomoniasis and bacterial vaginosis.
Serves as a Director at aditXt (since 2025), IMAC Holdings (since 2025), and Windtree Therapeutics, Inc. (since 2024).
Holds an Honorary Doctor of Business Administration and a Bachelor of Science in Business Administration.

Biography

Saundra Pelletier is the CEO of Evofem Biosciences, Inc., a commercial-stage biopharmaceutical company. Since 2013, she has led the company's commitment to developing and commercializing innovative products for unmet needs in women’s sexual and reproductive health. Under her leadership, Evofem Biosciences launched Phexxi in September 2020, the first and only FDA-approved hormone-free, on-demand birth control.